2023
PD-L1 expression as a unique negative predictive biomarker in advanced squamous NSCLC when treated with first-line chemotherapy.
Wong Zhun Hong N, Zhao J, Zhu K, Yap D, Kumarakulasinghe N, Huang Y, Sundar R. PD-L1 expression as a unique negative predictive biomarker in advanced squamous NSCLC when treated with first-line chemotherapy. Journal Of Clinical Oncology 2023, 41: e21140-e21140. DOI: 10.1200/jco.2023.41.16_suppl.e21140.Peer-Reviewed Original ResearchNon-small cell lung cancerPD-L1 expressionFirst-line chemotherapyNon-squamous non-small cell lung cancerSquamous non-small cell lung cancerTreated with first-line chemotherapyPhase III randomized trialNegative predictive biomarkerNon-squamous histologyPD-L1 subgroupsPD-L1Tumor progressionSquamous histologyPredictive biomarkersKaplan-MeierAdvanced squamous non-small cell lung cancerAdvanced non-small cell lung cancerPatients treated with first-line chemotherapyRandomized trialsInvestigated PD-L1 expressionRisk of tumor progressionHigh PD-L1Kaplan-Meier (KM) curvesPositive predictive biomarkerImmune checkpoint inhibition
2020
PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases
Kim G, Tan L, Sundar R, Lieske B, Chee C, Ho J, Shabbir A, Babak M, Ang W, Goh B, Yong W, Wang L, So J. PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases. Clinical Cancer Research 2020, 27: 1875-1881. PMID: 33148667, DOI: 10.1158/1078-0432.ccr-20-2152.Peer-Reviewed Original ResearchConceptsPressurized intraperitoneal aerosol chemotherapyPressurized intraperitoneal aerosolized chemotherapy proceduresPeritoneal cancer indexPeritoneal metastasisAerosol chemotherapyMedian peritoneal cancer indexPeritoneal Regression Grading ScoreRecommended phase II doseGrade 2 pancreatitisHighest-dose cohortPhase II doseDose-limiting toxicityFirst-line chemotherapyDose-escalation designTreat peritoneal metastasisPhase I studyImprove drug distributionII doseStable diseaseCancer indexMedian ageCohort expansionGastrointestinal tumorsPharmacokinetic analysisDose levels